Skip to main content

Market Overview

Inovio Shares Off 4% After EORTC Trial Enrollment Will Not Go Through


Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO) were trading lower by nearly 4 percent Tuesday morning after the company issued a clinical strategy update.

Inovio Pharmaceuticals stated that it will take its INO-3112 HPV immunotherapy into human studies in combination with selected immunotherapy molecules from MedImmune. The two companies will advance combination immunotherapies in populations with continued unmet need, the potential for a registerable endpoint and an expedient clinical path.

Related Link: Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price

Inovio Pharmaceuticals continued that with the new goals and objectives, it will no longer proceed with a previously planned enrollment of a European Organization for Research and Treatment of Cancer (EORTC) trial to study cervical cancer patients with INO-3112.

"HPV-related cancers represent an important unmet clinical need. We believe our combination immunotherapy approach with MedImmune could address a missing link in the spectrum of available and emerging treatment approaches. Following our ongoing preparations, we expect the initiation of the first clinical trial with this combination to be an important step for Inovio in 2016," said Dr. J. Joseph Kim, Inovio's President and CEO.

At time of writing, Inovio was down 1.25 percent at $7.92.


Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Cervical Cancer EORTCBiotech News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at